Abstract
In a first clinical trial with the apoptosis-inducing human antibody SC-1 eight patients with poorly differentiated stomach adenocarcinoma of diffuse-type received 20 or 30 mg of purified SC-1 antibody intravenously, followed 24 or 48 h later by gastrectomy and lymphadenectomy. In seven cases a significant induction of apoptotic activity was measured in primary tumors as compared with earlier biopsy material and in five patients a significant regression of tumor mass could be determined histopathologically. No toxic crossreactivity was observed with normal tissue or organs of patients.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / immunology
-
Adenocarcinoma / pathology
-
Adenocarcinoma / therapy*
-
Adult
-
Aged
-
Antibodies, Monoclonal / isolation & purification
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / isolation & purification
-
Antineoplastic Agents / therapeutic use*
-
Apoptosis / drug effects*
-
Combined Modality Therapy
-
DNA Fragmentation
-
Female
-
Gastrectomy
-
Humans
-
Immunotherapy*
-
Lymph Node Excision
-
Male
-
Middle Aged
-
Stomach Neoplasms / immunology
-
Stomach Neoplasms / pathology
-
Stomach Neoplasms / therapy*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
SC-1 monoclonal antibody